DiaMedica Therapeutics reported a net loss of $31.5 million for the nine months ended September 30, 2026, driven by increased research and development expenses for its lead candidate DM199. The company's cash and marketable securities decreased to $34.9 million from $59.9 million at the end of 2025, reflecting ongoing clinical trial costs for preeclampsia and fetal growth restriction programs.
DiaMedica Therapeutics reported Q3 2026 financial results and provided clinical updates on its DM199 programs. The company completed enrollment in the first two cohorts of its Phase 2 fetal growth restriction (FGR) trial and surpassed the 200-participant enrollment threshold for its ReMEDy2 Phase 2/3 acute ischemic stroke trial, with an interim analysis expected in Q1 2027.
Term
Q3 2026
“During the third quarter and recent weeks, we continued to advance DM199 across each of our clinical programs, including completing enrollment in the first two cohorts of our Phase 2 early-onset fetal growth restriction study and reaching the 200-participant enrollment threshold for the planned interim analysis of ReMEDy2.”
Rick Pauls, President and Chief Executive Officer
“Our clinical programs are providing important opportunities to evaluate the pharmacologic effects of DM199 across pregnancy-related vascular disorders and acute ischemic stroke.”